{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:35Z","timestamp":1792177715628,"version":"4.4.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Overactivation of the mineralocorticoid receptor (MR) promotes tissue remodeling in patients with heart failure (HF) and\/or chronic kidney disease (CKD). These patients may benefit from MR antagonists (MRAs); however, MRAs are underutilized, partly due to the risk of hyperkalemia. Balcinrenone is a novel, selective MR modulator that demonstrated renoprotection without an acute effect on urinary electrolyte excretion in preclinical studies, suggesting reduced hyperkalemia risk. Here, we present in vivo and in vitro studies comparing balcinrenone with eplerenone, an approved MRA. Myocardial perfusion reserve (MPR), an indicator of coronary microvascular remodeling, was evaluated in mice with diet-induced HF with preserved ejection fraction (HFpEF). MR target gene expression and markers of cardiac remodeling were evaluated using a clonal cell line of rat cardiomyocytes stably expressing MR (H9C2\/MR+), and inflammatory and fibrotic processes were evaluated in primary human cardiac fibroblasts. Potassium (K\n                    <jats:sup>+<\/jats:sup>\n                    ) homeostasis was evaluated in mice with nephrectomy-induced CKD. In mice with diet-induced HFpEF, 30 mg\/kg\/day balcinrenone or 100 mg\/kg\/day eplerenone restored MPR to levels seen in mice without HFpEF. Balcinrenone and eplerenone inhibited aldosterone-induced expression of MR target genes and markers of cardiac remodeling in H9C2\/MR+ cells, and excretion of collagen 1 and interleukin-6 in primary human cardiac fibroblasts, in a concentration-dependent manner. An overnight K\n                    <jats:sup>+<\/jats:sup>\n                    challenge in eplerenone-treated mice with nephrectomy-induced CKD yielded a higher plasma K\n                    <jats:sup>+<\/jats:sup>\n                    elevation than that observed in vehicle-treated CKD mice. By contrast, the plasma K\n                    <jats:sup>+<\/jats:sup>\n                    response in balcinrenone-treated mice with CKD was similar to what was observed in vehicle-treated CKD mice. Urinary K\n                    <jats:sup>+<\/jats:sup>\n                    excretion was not affected by balcinrenone or eplerenone treatment, but fecal K\n                    <jats:sup>+<\/jats:sup>\n                    excretion was elevated in CKD mice that were administered balcinrenone versus eplerenone. These results suggest that balcinrenone may be suitable for patients requiring additional cardiorenal protection through MR modulation but are at high risk of hyperkalemia.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0341078","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:37:31Z","timestamp":1770057451000},"page":"e0341078","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The novel mineralocorticoid receptor modulator balcinrenone protects against diet-induced cardiac microvascular dysfunction and plasma potassium elevation in mouse models"],"prefix":"10.1371","volume":"21","author":[{"given":"Matthew J.","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"El Moghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Palacios-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-6083","authenticated-orcid":true,"given":"Krister","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh A.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick H.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hartleib-Geschwindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"1","key":"pone.0341078.ref001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanisms of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"PJ Fuller","year":"2012","journal-title":"J Endocrinol"},{"issue":"3","key":"pone.0341078.ref002","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"E Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"pone.0341078.ref003","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0083-6729(03)01002-1","article-title":"Aldosterone: its receptor, target genes, and actions","volume":"66","author":"D Pearce","year":"2003","journal-title":"Vitam Horm"},{"issue":"1","key":"pone.0341078.ref004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"WW Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"pone.0341078.ref005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"J Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"pone.0341078.ref006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"J Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"issue":"7","key":"pone.0341078.ref007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030142","article-title":"Adverse effects of aldosterone: beyond blood pressure","volume":"13","author":"JM Brown","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0341078.ref008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"F Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"10","key":"pone.0341078.ref009","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"J-P Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"pone.0341078.ref010","first-page":"6","article-title":"Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives","volume":"3","author":"E Vizzardi","year":"2014","journal-title":"Int J Cardiol Heart Vessel"},{"issue":"1","key":"pone.0341078.ref011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"R Garg","year":"2015","journal-title":"Diabetes"},{"issue":"3","key":"pone.0341078.ref012","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/00325481.2022.2060598","article-title":"Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease","volume":"135","author":"E Lerma","year":"2023","journal-title":"Postgrad Med"},{"issue":"6","key":"pone.0341078.ref013","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"60","author":"AJ Rickard","year":"2012","journal-title":"Hypertension"},{"issue":"4","key":"pone.0341078.ref014","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"A Lother","year":"2011","journal-title":"Hypertension"},{"issue":"18","key":"pone.0341078.ref015","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"PA Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"pone.0341078.ref016","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"G Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"pone.0341078.ref017","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"pone.0341078.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"K Bamberg","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"pone.0341078.ref019","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ehjci\/jew315","article-title":"Diagnostic value of global myocardial perfusion reserve assessment based on coronary sinus flow measurements using cardiovascular magnetic resonance in addition to myocardial stress perfusion imaging","volume":"18","author":"Z Shomanova","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"pone.0341078.ref020","first-page":"246","volume-title":"Guide for the Care and Use of Laboratory Animals: Eighth Edition","author":"National Research Council","year":"2011"},{"issue":"5","key":"pone.0341078.ref021","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacbts.2022.11.005","article-title":"Obesity-induced coronary microvascular disease is prevented by iNOS deletion and reversed by iNOS inhibition","volume":"8","author":"SA Shah","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"pone.0341078.ref022","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/mrm.25238","article-title":"Accelerated dual-contrast first-pass perfusion MRI of the mouse heart: development and application to diet-induced obese mice","volume":"73","author":"NK Naresh","year":"2015","journal-title":"Magn Reson Med"},{"issue":"5","key":"pone.0341078.ref023","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mrm.20487","article-title":"Black blood gradient echo cine magnetic resonance imaging of the mouse heart","volume":"53","author":"SS Berr","year":"2005","journal-title":"Magn Reson Med"},{"issue":"4","key":"pone.0341078.ref024","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mrm.25018","article-title":"Motion-compensated compressed sensing for dynamic contrast-enhanced MRI using regional spatiotemporal sparsity and region tracking: Block LOw-rank Sparsity with Motion-guidance (BLOSM)","volume":"72","author":"X Chen","year":"2014","journal-title":"Magn Reson Med"},{"issue":"9","key":"pone.0341078.ref025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCRESAHA.121.320005","article-title":"Inhibition of DYRK1a enhances cardiomyocyte cycling after myocardial infarction","volume":"130","author":"A Young","year":"2022","journal-title":"Circ Res"},{"issue":"2","key":"pone.0341078.ref026","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCRESAHA.120.318277","article-title":"Loss of endogenously cycling adult cardiomyocytes worsens myocardial function","volume":"128","author":"LA Bradley","year":"2021","journal-title":"Circ Res"},{"issue":"10","key":"pone.0341078.ref027","first-page":"14904","article-title":"A convenient method for quantifying collagen fibers in atherosclerotic lesions by ImageJ software","volume":"10","author":"Y Chen","year":"2017","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"pone.0341078.ref028","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/en.2006-1438","article-title":"Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?","volume":"148","author":"G Fejes-T\u00f3th","year":"2007","journal-title":"Endocrinology"},{"issue":"9","key":"pone.0341078.ref029","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1210\/en.2010-0237","article-title":"Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart","volume":"151","author":"C Latouche","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"pone.0341078.ref030","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.111.187872","article-title":"Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system","volume":"59","author":"C Latouche","year":"2012","journal-title":"Hypertension"},{"issue":"12","key":"pone.0341078.ref031","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.3390\/ijms23126680","article-title":"Biglycan is a novel mineralocorticoid receptor target involved in aldosterone\/salt-induced glomerular injury","volume":"23","author":"T Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"pone.0341078.ref032","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"CSP Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"10518","key":"pone.0341078.ref033","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","article-title":"Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial","volume":"406","author":"HJL Heerspink","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"pone.0341078.ref034","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"L B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"2","key":"pone.0341078.ref035","doi-asserted-by":"crossref","first-page":"101972","DOI":"10.1016\/j.jocmr.2025.101972","article-title":"Multiparametric cardiac magnetic resonance identifies macrophage nitric oxide synthase 2-mediated benefits of preventive sodium-glucose cotransporter 2 inhibition in a mouse model of metabolic heart disease","volume":"27","author":"JE Bresticker","year":"2025","journal-title":"J Cardiovasc Magn Resonance"},{"issue":"11","key":"pone.0341078.ref036","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/eurheartj\/ehi795","article-title":"The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy","volume":"27","author":"F Rigo","year":"2006","journal-title":"Eur Heart J"},{"issue":"8","key":"pone.0341078.ref037","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/ehjci\/jev012","article-title":"Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes","volume":"16","author":"MD Majmudar","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"pone.0341078.ref038","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000289","article-title":"Mineralocorticoid receptor antagonists in cardiovascular translational biology","volume":"12","author":"RJ Chilton","year":"2023","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"4","key":"pone.0341078.ref039","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"Proteomic and mechanistic analysis of spironolactone in patients at risk for HF","volume":"9","author":"JP Ferreira","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"2","key":"pone.0341078.ref040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","article-title":"Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats","volume":"56","author":"GC Mel\u00e9ndez","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"pone.0341078.ref041","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41598-021-81388-0","article-title":"Increased colonic K+ excretion through inhibition of the H,K-ATPase type 2 helps reduce plasma K+ level in a murine model of nephronic reduction","volume":"11","author":"C Walter","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0341078.ref042","doi-asserted-by":"crossref","first-page":"14868","DOI":"10.1038\/s41598-021-94264-8","article-title":"A phosphate and calcium-enriched diet promotes progression of 5\/6-nephrectomy-induced chronic kidney disease in C57BL\/6 mice","volume":"11","author":"J Radloff","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0341078.ref043","first-page":"167","article-title":"Effects of 5\/6 nephrectomy on renal function and blood pressure in mice","volume":"4","author":"AL Gava","year":"2012","journal-title":"Int J Physiol Pathophysiol Pharmacol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:37:38Z","timestamp":1770057458000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341078"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341078","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}